Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
300 participants
INTERVENTIONAL
2020-11-02
2024-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS
NCT02827656
Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome
NCT01014104
Endometrial Receptivity After GnRH Agonist Triggering
NCT01500863
Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)
NCT02221154
Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells
NCT05330130
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
comparator group
myo-inositol treatment
Myo-inositol
Supplementation of myo-inositol (4 g/die), starting at least 4 weeks before rFSH administration
study group
D-chiro-inositol treatment
D-chiro-inositol
Supplementation of D-chiro-inositol (1000 mg/die), starting at least 4 weeks before rFSH administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-chiro-inositol
Supplementation of D-chiro-inositol (1000 mg/die), starting at least 4 weeks before rFSH administration
Myo-inositol
Supplementation of myo-inositol (4 g/die), starting at least 4 weeks before rFSH administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HOMA-IR index \< 2.0
* AMH in the range 1.0 - 2.0 ng/ml
Exclusion Criteria
* BMI \< 20 kg/m2 or ≥ 30 kg/m2
* Diagnosis of PCOS
* Thyroid diseases
* Presence of co-morbidities
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lo.Li.Pharma s.r.l
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinica Alma Res
Roma, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MI_DCI_FSH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.